Facilities for Personalised Medicine in the Most Personal Form – Today and Tomorrow written by Henriette Schubert, Global Technology Partner NNE A/S

When redoing the batch is not an option There is a paradigm shift underway in which big pharma mass production of products for specific diseases is deviating towards the ‘batch of one.’ These autologous therapies are patient-specific and there may only be one chance to harvest the patient’s ce...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy



Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy